Stock code: 300759.SZ

Stock code: 3759.HK

2026

Interim Results

August 2026Disclaimer

The documents opinions and materials presented in this presentation (the “Document”) have been prepared by Pharmaron Beijing Co. Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”) for use in

presentations by the Company and does not constitute a recommendation regarding the securities of the Company. You fully understand that the Document is being made available on a confidential basis and subject to

the following provisions. The contents of this Document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this Document in certain jurisdictions may be restricted by law and the

recipients into whose possession this Document comes should inform themselves about and observe such restrictions. By accessing this Document you are agreeing (i) that you have read and agree to comply with the

contents of this notice and disclaimer and (ii) to maintain absolute confidentiality regarding the information disclosed in this Document.This Document has not been independently verified and is not intended to form the basis of any investment decision. It does not constitute an offer or invitation to sell or any solicitation of any offer to subscribe for or

purchase any securities in any jurisdiction in which the making of such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise

be in compliance with the laws and regulations of such jurisdiction and nothing contained herein shall form the basis of any investment decision contract or commitment whatsoever. This Document contains no

information or material which may result in it being deemed (1) to be an advertisement invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and

Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “Securities and Futures Ordinance”) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being

able to invoke any exemption available under the laws of Hong Kong and is subject to material change without notice.The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933 as amended (the “U.S. Securities Act”) or under the laws of any state of the United States. This Document

does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States and is not for distribution and may not be distributed directly or indirectly in or into the United

States (including its territories and possessions any state of the United States and the District of Columbia). The securities of the Company will not be offered or sold in the United States except pursuant to an

exemption from or in a transaction not subject to the registration requirements of the U.S. Securities Act. There will be no public offer of the Company’s securities in the United States.This Document and the information contained herein as well as information presented orally or otherwise are strictly confidential and must be treated as such. Neither the information contained in this Document nor any

copy hereof may be directly or indirectly taken or transmitted into or distributed in the United States Canada Australia Japan PRC Hong Kong or any other jurisdiction which prohibits the same except in compliance

with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other jurisdiction's securities laws. Upon request the recipient will promptly return this Document and any

other written information made available in the presentation without retaining any copies.This Document does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the Group. No representation warranty or undertaking express or implied is given

and so far as is permitted by law no responsibility or liability is accepted by any person (for the avoidance of doubt including but not limited to the Company and its affiliates controlling persons directors officers

partners employees agents representatives or advisers of any of the foregoing) with respect to the accuracy reliability correctness fairness or completeness of this Document or its contents. The information

communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will" "expects" “intends” “plans to” and "anticipates" and words of

similar import. These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about the Company’s operations and factors beyond the

Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ materially from these forward-looking statements. In particular but without limitation no representation

or warranty is given as to the achievement or reasonableness of and no reliance should be placed on any assumptions projections targets estimates forecasts or any forward-looking statements contained in this

Document. Each of the Company and its affiliates controlling persons directors officers partners employees agents representatives or advisers of any of the foregoing assumes no obligation to update or otherwise

revise these forward-looking statements for new information events or circumstances that occur subsequent to such dates. None of the Company and any of its affiliates controlling persons directors officers partners

employees agents representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of or reliance upon the information contained herein by you or any person

to whom the information herein is disclosed.In furnishing this Document the Company and its affiliates undertake no obligation to provide any additional information or to update this Document or any additional information or to correct any inaccuracies which may

become apparent.

2C o n t e n t s

Performance Segment Financial Future

Overview Highlights Highlights Outlook

31234

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

42Q2026 Revenue and Adjusted Net Profit Growth Remain Robust

RMB mm 2Q2026 1Q2026 QoQ 2Q2025 YoY

Revenue 4017 3578 12.3% 3342 20.2%

Net Profit 415 335 23.7% 396 4.8%

Non-IFRS Adjusted Net Profit 503 406 23.8% 406 23.8%

? Revenue & Non-IFRS adjusted net profit growth both accelerated in 2Q2026 compared to

1Q2026

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 51H2026 Financials & 2026 Outlook

RMB mm 1H2026 1H2025 YoY

Revenue 7595 6441 17.9%

Net Profit 750 701 7.0%

Non-IFRS Net Profit 909 756 20.3%

? New POs: new POs increased by 30%+ YoY

? MNC Customers: revenue from TOP20 Pharmas increased by 32.0% YoY

? Guidance: raise 2026 revenue growth guidance to 15-20%

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 61H2026 Highlights

Global Platform & Customers Rich Pipeline to Fuel Future Growth

470+ new customers in 1H2026 3400+ active Discovery projects: 811 drug discovery

customers TTM incl. all TOP20 global pharmas projects

28 R&D & Mfg. facilities in CN UK & US. 27316 SM CDMO projects: 45 in PPQ & commercial

emps. incl. 1700+ overseas emps. 24953 51 in PhIII 238 in PhI/II 448 in preclinical

scientists & technicians representing 91%+ of

Clinical CRO projects: 1357 CRO projects incl.total emps.

132 in PhIII 589 in PhI/II and 636 other projects

Enabling customers with cutting-edge (incl. PhIV IIT &RWS)

technologies: strengthen lab/CDMO capabilities

SMO projects: 2200+ projects CRC team

for new modalities; enhance NAM platform;

covers 700+ hospitals & clinical trial centers in

advance AI & automation adoption; explore

150+ cities

quantum computing for CADD with Logic Qubit

& ZJU.; explore embodied intelligent robots for

R&D and Mfg. workflows with AI2 Robotics

71H2026 Revenue Compositions

Segments Revenue Composition Global Customers Revenue Composition

ROW 3%

Clinical Development Customers from NA

Services 14% Revenue Grew 14.8%

Mainland

Customers from EU China

18%

Revenue Grew 6.0% North

CDMO Services Laboratory America

25% Services Customers from Mainland CN 62%Europe

61% Revenue Grew 41.9% 17%

China/Overseas Entities Revenue Composition Diversified Customer Base Revenue Composition

New Customers

2%

China Entities Overseas TOP20 Pharmas TOP20

Revenue Grew 20.7% 10% Revenue Grew 32.0% Pharmas

20%

Overseas Subsidiaries Other Customers

Revenue Declined 1.9% Revenue Grew 14.8%

Other Repeat Customers

China

78%

90%

8ESG Updates

ESG Ratings ISO Cert. & UNGC Sustainable Development

* Obtained expanded certifications for * Included in S&P Global

the ISO 27001 ISO 14001 ISO Sustainability Yearbook

2025 MSCI ESG Rating 45001 & ISO 22301 * Awarded the title of “IndustryAA Mover” by S&P Global

SUSTAINALYTICS

2025 Low Risk Company; 2026 Joined in the United Nations 2025 EcoVadis

Industry ESG Leader Regional ESG Global Compact (UNGC) Silver Prize

Leader Global ESG Leader

91234

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

10Accelerating Platform Integration to Strengthen New Modality Service Capabilities

The complexity of drug candidates is rising while the distinctions between molecular modalities are fading

Small Molecule Peptide & Oligo Biologic & Bioconjugate Cell & Gene Therapy

Greater complexity & Long-chain synthesis + Antibody / peptide + Linker + Cell therapy / gene vector +

developability challenges chemical modification + delivery small molecule delivery & release

As conjugation modification & delivery technologies converge a single platform cannot meet the R&D needs

Accelerating CRO & CDMO platform integration to address R&D demands

Synergized Lab Services CDMO Platform Technology Integration Integrated Services

Synergizing synthesis Integrated PD & commercial- Integration of small molecule End-to-end integrated delivery

analytical & bioassay platforms scale manufacturing & new modality capabilities for enhanced efficiency

11Synergies Across Three Segments to Accelerate R&D of Multi-Modality Therapeutics

Laboratory Services CDMO Services Clinical Dev. Services

Discovery (PCC) Preclinical (IND) Clinical (NDA/BLA) Commercial

Laboratory Chemistry Early Dev. of DS & DP DS & DP Production DS & DP Production

In vitro Biology In vitro Biology PhI–III Clinical Dev. PhIV & Post-mkt.In vivo Pharmacology In vivo Pharmacology Clinical 14C-ADME

Small Molecule DMPK DMPK PK/Bioanalytical/Biomarkers

(Incl. Peptide)

Exploratory Tox Safety Assessment

Biologics Discovery Developability Assess. DS & DP Production DS & DP Production

Protein Prod. & Char. Proc. Scale-up & Prod. Immunogenicity PhIV & Post-mkt.In vitro Biology HP/PD PhI–III Clinical Dev.In vivo Pharmacology Immunogenicity PK/Bioanalytical/Biomarkers

Biologic &

HP/PD Safety Assessment

Bioconjugate

Immunogenicity/Toxicity

In vitro Biology Early Proc./Form. Dev. Gene Therapy Mfg. Gene Therapy Mfg.In vivo Pharmacology Viral Shedding Analysis Viral Shedding Analysis In vitro Release Test

Candidate Cloning In vitro Potency In vitro Release Test PhIV & Post-mkt.HP/PD PK/PD/Tissue Distribution Immunogenicity

CGT

Immunogenicity Immunogenicity PhI–III Clinical Dev.(Incl. oligo)

Exploratory Tox Safety Assessment PK/Bioanalytical/Biomarkers

12

Large-scale production capacities for peptides oligonucleotides and bioconjugates are currently under constructionLaboratory Services

RMB mm 2Q2026 1Q2026 QoQ 2Q2025 YoY 1H2026 1H2025 YoY

Revenue 2430 2204 10.2% 2132 13.9% 4634 4075 13.7%

GPM 39.8% 41.7% -1.9pct 42.0% -2.2pct 40.7% 42.4% -1.7pct

? Solid growth of lab chemistry services. Strong growth of bioscience services especially new

modality business. Bioscience services accounted for 60%+ of the segment’s total revenue

? New POs grew by 20%+ YoY

? Participated in 811 drug discovery projects

? Continuing capacity expansion to support mid-to-long-term demand with Beijing Campus III

coming online and Ningbo Campuses III & IV on track

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 13CDMO Services

RMB mm 2Q2026 1Q2026 QoQ 2Q2025 YoY 1H2026 1H2025 YoY

Revenue 1012 872 15.9% 712 42.0% 1884 1419 32.8%

GPM 26.8% 24.1% 2.7pct 23.4% 3.4pct 25.6% 22.9% 2.7pct

? Strong synergies: 85%+ of CDMO revenue came from customers of lab services

? New POs grew by 50%+ YoY. Significant progress in large-scale SM CDMO services with

more projects expected to be delivered in 2H2026

? Milestones in commercial manufacturing: (1) signed a commercial manufacturing agreement

with an MNC for an oral GLP-1 DP. (2) API facility in Ningbo passed its first NMPA PAI

? Accelerating capacity expansion of SM CDMO services in Shaoxing & Hangzhou. Continuing

to strengthen integrated CDMO capabilities for peptides & bioconjugates

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 14Small Molecule CDMO Projects Continued to Advance to Late Stage

Total +141

+39

448 Preclinical

+50

238 Phase I/II

+30

51 Phase III

+22

45 PPQ & Comm.

15Clinical Development Services

RMB mm 2Q2026 1Q2026 QoQ 2Q2025 YoY 1H2026 1H2025 YoY

Revenue 568 500 13.7% 492 15.5% 1069 939 13.8%

GPM 12.1% 7.1% 5.0pct 12.8% -0.7pct 9.8% 12.3% -2.5pct

? New POs grew by 30%+ YoY

? 1357 CRO projects incl. 132 PhIII trials 589 PhI/II trials & 636 other clinical trials

? 2200+ SMO projects. CRC team covered 700+ hospitals & clinical trial centers in 150+ cities

? Continuously improving productivities through refined operations and the adoption of digital &

AI-enabled tools

? Controlling subsidiary Aistarfish achieved meaningful scale in real-world patient management

& RWS service orders and partnered with top-tier domestic hospitals for RWS collaborations

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 161 2 3 4

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

171H2026 Expenses for the Period

Selling and Distribution Expenses as % of Total Revenue Administrative Expenses as % of Total Revenue (1)

12.7%12.8%12.6%12.7%12.0%

2.2%2.1%2.2%2.2%2.2%

2023 2024 2025 1H2025 1H2026 2023 2024 2025 1H2025 1H2026

R&D Costs as % of Total Revenue Net Finance Costs as % of Total Revenue (2)

1.0%

0.9%0.9%0.9%

3.9%4.1%3.8%3.9%3.9%

0.1%

2023 2024 2025 1H2025 1H2026 2023 2024 2025 1H2025 1H2026

1. Excluding share-based compensation expenses and one-off reorganization-related expenses recognized in administrative expenses 18

2. Net finance costs including interest expenses on bank borrowings and lease liabilities interest income and bank wealth management products related gains or lossesScaling Capacity & Supply to Meet Growing Customer Demand

RMB mm

3221

2865

2754

25772669

2041

14081368

11541085

2023 2024 2025 1H2025 1H2026

Net Operating Cash Flow CAPEX

191H2026 Non-IFRS Adjusted Net Profit

RMB mm 1H2026 1H2025

Net Profit 750 701

Add:

Share-based Compensation Expenses 37 26

Foreign Exchange Related Losses 104 23

Realized and Unrealized (Gains) /Losses from Equity

(31)5

Investments

Amortization of Intangible Assets from Acquisitions 15 1

One-off Reorganization-related Expenses 34 -

Non-IFRS Adjusted Net Profit 909 756

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million 201 2 3 4

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

212026 Outlook

The evolving healthcare demands and technological innovations will sustain the

development of our industry. Global customer demand continue to demonstrate resilience

while demand from China customers is showing signs of recovery

Continue to develop our end-to-end fully integrated and multiple modalities-capable

service platform commit to the CRDMO business model across the entire drug lifecycle

and deepen the integration of AI & automation across operations to drive sustained growth

Raise 2026 revenue growth guidance to 15-20%

Disclaimer: These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about

the Company’s operations and factors beyond the Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ 22

materially from these forward-looking statementsTHANK YOU